Genomic and Molecular Cardiovascular Medicine

*4 stars* "...a multi-authored reference text on application of biomaterials in the treatment of cardiovascular diseases.... [C]ompiles information from clinical reviews and experimental trials to address the vital role that biomaterials play in modern therapies for cardiovascular diseases (CVD). This compilation details the applications of various materials in the context of specific cardiovascular structural and electrophysiological pathologies, highlighting potential limitations alongside potential future applications.... This book effectively bridges the gap between disciplines, offering enough background and context for non-clinicians to grasp the clinical applications and for non-engineers to understand the material and engineering aspects. It presents a unique intersection of fields, delivering a comprehensive analysis of the evolution and expansion of biomedical therapies. Additionally, the book inspires forward-thinking on how future innovations in biomedical materials could further enhance the treatment of cardiovascular diseases." --©Doody s Review Service, 2024, Manar Jbara, MD (East Tennessee State University Quillen College of Medicine)

Professor Kumar has considerable previous experience in writing and editing books and journals related to genetics and genomics. His books include Genomics and Clinical Medicine and Genomics and Health in the Developing World. He founded and leads the new open access journal Applied and Translational Genomics, published by Elsevier. He has published 40 articles in the journals literature.

Professor Dhavendra Kumar is a Visiting Professor, Genomic Policy Unit, Faculty of Life Sciences and Education, The University of South Wales and Consultant in Clinical Genetics at the University Hospital of Wales, Institute of Medical Genetics, Cardiff University, Cardiff, United Kingdom. He is one of the Consultants for the All Wales Medical Genetics Service and the lead Clinician for Clinical Cardiovascular Genetics. After qualifying in Medicine from the King George's Medical College, University of Lucknow, India, he completed postgraduate training in Pediatrics with an MD. Since 1980 he has pursued a career in Medical Genetics in the UK. In 1990 he became a Diplomate of the American Board of Medical Genetics. He is a Fellow of the American College of Medical Genetics (FACMG) and as well as Royal Colleges of Physicians (FRCP-London and FRCP-Ireland) and Pediatrics and Child Health (FRCPCH-UK).

In 2015, he was conferred with the higher degree of DSc by his Alma Mater, King George's Medical University, Lucknow (UP, India) based on his life-time contributions and achievements to genetic and genomic applications in medicine and health.

Dr. Arthur A. M. Wilde is a clinical Cardiologist and translational researcher with a focus in electrophysiology, cardiogenetics and inherited arrhythmias. In Amsterdam University Medical Centers (location AMC), his lab is one of the first worldwide to start an outpatient cardiogenetic clinic. Over the years they have seen thousands of patients and families with inherited arrhythmia syndrome. This is the basis of his Academic Research, which is focused on inherited cardiac diseases which are associated with sudden cardiac death. Different aspects, including gene discovery, genotype-phenotype relationships and new treatment modalities have been and are being covered. Dr. Wilde has been the coordinator of the European Reference Network GUARD-Heart (The ERN for rare cardiac diseases) since 2017.
Perry Elliott) is Professor of Cardiovascular Medicine and director of the Centre for Heart Muscle Disease at University College London (UCL) and a consultant cardiologist in the Centre for Inherited Cardiovascular Disease at St. Bartholomew's Hospital London, UK. He is Chairman of the ESC Heart Academy and the ESC Council on Cardiovascular Genomics. He is past Chairman of the ESC Working Group on Myocardial and Pericardial Diseases (2010-2012), the Executive Committee for the European Outcomes Research Programme (EORP) registry on cardiomyopathies and the ESC Guideline Task Force on Hypertrophic Cardiomyopathy. He is President of Cardiomyopathy UK, Europe's foremost charity for patients with heart muscle disease. Over the past 25 years, Prof. Elliott has established an international reputation in the field of heart muscle disease, authoring more than 500 peer-reviewed papers on the subject. He develops diagnostic standards, risk stratification tools and clinical service models.